3D cell culture alters signal transduction and drug response in head and neck squamous cell carcinoma.
HER3 expression
afatinib
epidermal growth factor receptor
lapatinib
spheroid culture
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
30
12
2021
accepted:
23
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
ppublish
Résumé
Epidermal growth factor receptor (EGFR) upregulation is a typical characteristic of head and neck squamous cell carcinoma (HNSCC). However, tyrosine kinase inhibitors have not yet been able to achieve enough therapeutic benefit in clinical trials to justify their use in standard therapy regimens. At present, little is known about the reasons for this treatment failure. In the present study, the HNSCC cell lines UM-SCC-11B and UM-SCC-22B were tested for their response to tyrosine kinase inhibitors (TKI) under 2D and 3D cell culture conditions. Absorption and luciferase-based viability assays were used for this, as well as optical evaluation via fluorescence microscopy. In addition, EGFR and HER3 expression as well as the downstream signalling pathways PI3K/AKT/mTOR and RAS/RAF/MEK/ERK were investigated using western blotting. Cell line UM-SCC-11B revealed a strong resistance to lapatinib under 3D cell culture conditions, while a good response to TKI therapy was observed under 2D cell culture conditions. An associated overexpression of phosphorylated HER3 under 3D cell culture conditions offered a plausible explanation for the altered treatment response. The results of the present study represent an idea of how signalling mechanisms of cancer cells can be changed using different cell culture methods. Overall, 3D cell culture could be an important component in the analysis of resistance mechanisms in cancer therapy.
Identifiants
pubmed: 35464304
doi: 10.3892/ol.2022.13297
pii: OL-23-06-13297
pmc: PMC9021830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177Informations de copyright
Copyright: © Heid et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Crit Rev Oncol Hematol. 2016 May;101:151-7
pubmed: 27017409
Oncol Rep. 2016 Apr;35(4):2431-40
pubmed: 26797047
Laryngorhinootologie. 2021 Jan;100(1):23-29
pubmed: 33401320
Clin Cancer Res. 2017 Feb 1;23(3):677-686
pubmed: 27358485
Oncol Lett. 2018 May;15(5):7497-7505
pubmed: 29725456
Cancer. 2016 Aug 1;122(15):2350-5
pubmed: 27197056
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
Life Sci. 2020 May 15;249:117483
pubmed: 32135187
J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474
pubmed: 32567494
Expert Opin Investig Drugs. 2014 Jan;23(1):135-43
pubmed: 24266694
Neurooncol Adv. 2021 May 07;3(1):vdab065
pubmed: 34142085
Cancer Treat Rev. 2014 May;40(4):567-77
pubmed: 24216225
Cancer Res. 1988 Jun 1;48(11):3282-7
pubmed: 3365707
Stem Cell Rev Rep. 2021 Oct;17(5):1810-1826
pubmed: 33893620
BMJ Open. 2017 Mar 13;7(3):e013053
pubmed: 28289045
Cancer Res. 1993 Aug 1;53(15):3579-84
pubmed: 8339264
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
Sci Rep. 2019 Aug 28;9(1):12480
pubmed: 31462653
Oncol Lett. 2014 Jan;7(1):82-86
pubmed: 24348826
Cancer Med. 2019 Mar;8(3):1258-1268
pubmed: 30701699
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
pubmed: 17210912
BMC Cancer. 2018 May 24;18(1):592
pubmed: 29793440
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987257
J Surg Oncol. 2019 May;119(6):685-686
pubmed: 30701564
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Anticancer Res. 2021 Mar;41(3):1261-1269
pubmed: 33788717
Nat Rev Cancer. 2020 Jul;20(7):398-411
pubmed: 32488200
Biomaterials. 2015 Jul;55:110-8
pubmed: 25934456
Am J Cancer Res. 2020 Sep 01;10(9):2742-2751
pubmed: 33042614
Chemother Res Pract. 2014;2014:357027
pubmed: 24963404
Mol Cancer Ther. 2016 Sep;15(9):2175-86
pubmed: 27422810
Ann Oncol. 2019 Nov 1;30(11):1831-1839
pubmed: 31501887
Head Neck. 2010 Sep;32(9):1195-201
pubmed: 20073073
Semin Oncol. 2004 Dec;31(6):726-33
pubmed: 15599850
Clin Cancer Res. 2006 Sep 15;12(18):5268-72
pubmed: 17000658
Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110264
pubmed: 31761183
Ann Oncol. 2017 Oct 01;28(10):2526-2532
pubmed: 28961833